Will Medicare cover GLP-1 weight-loss drugs starting July 1, 2026?

Yes — starting July 1, 2026, Medicare will make some GLP-1 weight-loss drugs available through a temporary Centers for Medicare & Medicaid Services program called the Medicare GLP-1 Bridge. But this is not a broad new obesity-drug benefit for everyone on Medicare. It applies only to certain people with Medicare Part D coverage who meet CMS clinical rules.

CMS says the Bridge is a short-term, nationwide demonstration that will run from July 1, 2026, through December 31, 2027. It is separate from the regular Medicare Part D benefit, which matters because some GLP-1 prescriptions are still supposed to go through normal Part D coverage instead of the Bridge.

This is a practical issue for many older adults. CDC says more than 2 in 5 U.S. adults have obesity, and obesity prevalence among adults age 60 and older was 41.5% in the most recent federal figures listed on that page. Obesity is also linked with other chronic conditions that show up in CMS’s eligibility rules.

What starts July 1, 2026

CMS says the Medicare GLP-1 Bridge will be available in all states and territories starting July 1, 2026. Beneficiaries do not have to register or opt in. As of June 20, 2026, CMS says more beneficiary instructions are being released ahead of launch. JAMA described the program as a time-limited pilot intended to lower the monthly cost of certain GLP-1 weight-loss medicines for eligible Medicare beneficiaries.

Which drugs are included

Right now, CMS lists three eligible products when they are prescribed to reduce excess body weight and maintain weight reduction: Foundayo, Wegovy, and Zepbound. But the exact formulation matters. CMS says all Foundayo formulations and all Wegovy formulations are included, while only the Zepbound KwikPen formulation is included. The single-dose vial and single-dose pen versions of Zepbound are not part of the Bridge.

CMS notes that it updated the Bridge list in April 2026 to add Foundayo after FDA approval. That helps explain why the oral drug appears alongside the injectable options in the current CMS materials.

Who qualifies

First, the Medicare drug coverage type has to fit. CMS says the Bridge is for people enrolled in a standalone Part D prescription drug plan or a Medicare Advantage coordinated care plan with drug coverage. Some other Part D arrangements, including Special Needs Plans, employer or union group waiver plans, and the LI NET program, can also qualify. Several other plan types do not qualify unless the person is also enrolled in a standalone Part D plan.

Second, a medical provider has to submit a prior authorization request attesting that the patient meets the Bridge clinical criteria. CMS says the drug must be prescribed for weight management together with ongoing lifestyle modification, including nutrition and physical activity, consistent with the FDA-approved label.

CMS lists three main clinical pathways, based on the patient’s status when GLP-1 therapy began:

Age 18 or older with a body mass index, or BMI, of 35 or higher at the start of GLP-1 therapy.
Age 18 or older with a BMI of 30 or higher at treatment start plus at least one of these diagnoses: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher.
Age 18 or older with a BMI of 27 or higher at treatment start plus prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.

One detail matters a lot: CMS ties eligibility to the clinical picture when treatment started, not only to the patient’s weight in July 2026 or later. So a person who began treatment at a higher BMI may still qualify even if their BMI is lower by the time the prior authorization is filed.

What the $50 copay really means

CMS says eligible beneficiaries will pay $50 a month for drugs furnished under the Bridge, but that does not work like a normal Part D fill. The Part D deductible does not apply. The $50 copay does not count toward true out-of-pocket spending under Part D. Low-income subsidy reductions do not apply to that copay either.

CMS also says the manufacturer net price and the beneficiary copay under the Bridge do not count toward normal Part D spending totals. In plain language, the Bridge may lower the price at the pharmacy counter for some people, but it does not move a beneficiary through the regular Part D benefit phases the way an ordinary covered prescription would. JAMA noted that list prices for these medicines are often above $1,000 a month, which helps explain why the fixed $50 price point is getting so much attention.

Why the same drug may be covered differently depending on diagnosis

The biggest catch is the reason the drug is being prescribed. CMS says the Bridge is only for people seeking a GLP-1 solely to reduce excess body weight or maintain weight reduction. If the same drug is being prescribed for a use that is already coverable under Medicare Part D, it is supposed to go through regular Part D coverage instead of the Bridge.

CMS gives examples. Zepbound prescribed for moderate to severe obstructive sleep apnea in adults with obesity belongs under regular Part D coverage, not the Bridge. Wegovy prescribed to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight also belongs under regular Part D coverage. CMS likewise says type 2 diabetes and noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, are Part D-covered indications rather than Bridge uses.

That means two people could be prescribed a similarly branded GLP-1 product and still have different Medicare coverage paths depending on the diagnosis attached to the prescription.

How prior authorization works

CMS says an eligible beneficiary will need both a prescription and a prior authorization request from a medical provider. The request can be submitted electronically or by fax. CMS also says requests will not be accepted or processed before July 1, 2026.

The provider does not have to be enrolled in Medicare to prescribe the drug or submit the prior authorization request. But CMS says the provider cannot be on Medicare’s Preclusion List. For many patients, the practical work will be making sure the chart documents the starting BMI, any qualifying conditions, the intended diagnosis, and the exact product formulation.

What readers can do now

Check what kind of Medicare drug coverage you have, because Bridge eligibility starts with plan type.
If you already use a GLP-1 drug, ask your prescriber which diagnosis is attached to it. That may determine whether the prescription belongs under regular Part D coverage or the Bridge.
Ask whether your starting BMI and any qualifying conditions are clearly documented in the medical record, since CMS bases Bridge eligibility on when therapy began.
Before expecting a $50 fill, ask your prescriber or plan how the prior authorization will be handled and whether your exact product formulation is on the Bridge list.
If you are unsure what Part D arrangement you have, Medicare or your State Health Insurance Assistance Program may be able to help you sort that out.
Do not start, stop, or switch a prescription medicine based only on insurance headlines. Those decisions should go through your own clinician.

Bottom line

Medicare is opening a temporary path to lower-cost GLP-1 weight-loss drugs on July 1, 2026, but only for some Part D beneficiaries and only under CMS’s Bridge rules. What is clear now is the start date, end date, listed drugs, basic eligibility criteria, and the fixed $50 copay. What is still likely to feel plan-specific for many people is the real-world workflow: confirming the diagnosis, matching the right formulation, and getting prior authorization submitted correctly. Because the demonstration ends on December 31, 2027, it should not be mistaken for a permanent Medicare obesity-drug benefit.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.